公开(公告)号：US20180021288A1

公开(公告)日：2018-01-25

申请号：US15644029

申请日：2017-07-07

Applicant: Biogen MA Inc.

Inventor： Susan Goelz ,  Katherine Dawson ,  Ralf Linker ,  Ralf Gold

IPC: A61K31/225 ,  A61K31/194 ,  A61K9/28 ,  A61K31/785 ,  A61K38/02 ,  A61K9/48 ,  A61K38/21 ,  A61K9/20

CPC classification number: A61K31/225 ,  A61K9/2072 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/194 ,  A61K31/785 ,  A61K38/02 ,  A61K38/215 ,  A61K2300/00

Abstract: Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: wherein R1 and R2 are independently selected from OH, O−, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.

公开(公告)号：US20160250172A1

公开(公告)日：2016-09-01

申请号：US15057836

申请日：2016-03-01

Applicant: Biogen MA Inc.

Inventor： Susan Goelz ,  Katherine Dawson ,  Ralf Linker ,  Ralf Gold

IPC: A61K31/225 ,  A61K31/785 ,  A61K31/194

CPC classification number: A61K31/225 ,  A61K9/2072 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/194 ,  A61K31/785 ,  A61K38/02 ,  A61K38/215 ,  A61K2300/00

Abstract: Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: wherein R1 and R2 are independently selected from OH, O−, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.

Abstract translation: 提供治疗神经系统疾病的方法，例如由脱髓鞘和/或轴突损失（例如MS）表征的那些。 所述方法包括施用治疗有效量的至少一种式I化合物：其中R 1和R 2独立地选自OH，O-和（C 1-6）烷氧基，或其药学上可接受的盐; 和醋酸格拉默或干扰素-β。

公开(公告)号：US20180271821A1

公开(公告)日：2018-09-27

申请号：US15989683

申请日：2018-05-25

Applicant: Biogen MA Inc.

Inventor： Ralf Gold

IPC: A61K31/225

CPC classification number: A61K31/225

Abstract: Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate.